Commonwealth Equity Services’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Commonwealth Equity Services’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-951	Closed	-$241K	–	3204
2020 Q3	$241K	Buy	+951	New	+$195K	﹤0.01%	2546
2020 Q1	–	Sell	-791	Closed	-$50K	–	2826
2019 Q4	$50K	Buy	791 +7	+0.9%	+$406	﹤0.01%	2801
2019 Q3	$45K	Hold	784	–	–	﹤0.01%	2747
2019 Q2	$46K	Hold	784	–	–	﹤0.01%	2701
2019 Q1	$51K	Hold	784	–	–	﹤0.01%	2658
2018 Q4	$41K	Hold	784	–	–	﹤0.01%	2578
2018 Q3	$44K	Hold	784	–	–	﹤0.01%	2702
2018 Q2	$46K	Hold	784	–	–	﹤0.01%	2663
2018 Q1	$37K	Hold	784	–	–	﹤0.01%	2615
2017 Q4	$46K	Buy	784 +33	+4%	+$1.97K	﹤0.01%	2573
2017 Q3	$46K	Hold	751	–	–	﹤0.01%	2473
2017 Q2	$47K	Buy	+751	New	+$46.3K	﹤0.01%	2422

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Commonwealth Equity Services's BCLI Position: Q4 2020 in Review

Commonwealth Equity Services sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2020, closing a stake of 951 shares — an estimated $241K sold.

Commonwealth Equity Services first reported a position in BCLI in Q2 2017 and held it in 12 quarters. The position peaked at $241K in Q3 2020. 90 funds tracked by Wall St. Rank hold BCLI as of Q4 2020.

Commonwealth Equity Services reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2020 after selling out during the quarter.
Commonwealth Equity Services sold 951 BRAINSTORM CELL THERAPUTC shares in Q4 2020, an estimated $241K.
Commonwealth Equity Services first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2017 and held it in 12 quarters.
Commonwealth Equity Services's BRAINSTORM CELL THERAPUTC position peaked at $241K in Q3 2020.
90 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2020.

Based on Commonwealth Equity Services's 13F filing for Q4 2020, filed 11 Feb 2021.